Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications

Platelets

Volumn 24, Issue 8, 2013, Pages 605-614

  Tantawy, Azza Abdel Gawad ^a   Adly, Amira Abdel Moneam ^a   Ismail, Eman Abdel Rahman ^a   Habeeb, Nevin Mamdouh ^a   Farouk, Amal ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Aortic distensibility; Aortic stiffness; Microparticles; Pulmonary hypertension; Sickle cell disease

Indexed keywords

ANTITHROMBIN III; D DIMER; FERRITIN; VON WILLEBRAND FACTOR;

ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ERYTHROCYTE; ERYTHROCYTE MICROPARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEART LEFT VENTRICLE FUNCTION; HEMOLYSIS; HUMAN; LEUKOCYTE COUNT; LUNG ARTERY PRESSURE; MALE; MEMBRANE MICROPARTICLE; PLATELET MICROPARTICLE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCHOOL CHILD; SICKLE CELL ANEMIA; SPLENECTOMY; STEADY STATE; THROMBOCYTE; THROMBOSIS;

ADOLESCENT; ANEMIA, SICKLE CELL; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; ERYTHROCYTES; FEMALE; HUMANS; MALE;

EID: 84885933798     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.749397     Document Type: Article

References (76)

1. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343-1360.
2. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 2003;289:1136-1142.
3. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000;22:515-520.
4. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon III RO. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003;107:271-278.
5. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001;97:1584-1589.
6. Morris CR, Morris SMJ, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
7. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes Jr J, Shah AK, Mankad VN. Investigators of the cooperative study of sickle cell disease. Causes of death in sickle cell disease: An autopsy study. Br J Haematol 2003;123:359-365.
8. Acar P, Maunoury C, de Montalembert M, Dulac Y. Abnormalities of myocardial perfusion in sickle cell disease in childhood: A study of myocardial scintigraphy. Arch Mal Coeur Vaiss 2003;96:507-510.
9. O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995;26:2-9.
10. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-1241.
11. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, Lacombe C, Galacteros F, Adnot S. Endothelial dysfunction in patient with sickle cell disease is related to selective impairment of shear stress-mediated vasodilatation. Blood 2001;97:1584-1589.
12. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: New approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007;2007:91-96.
13. Francis RB. Platelets, coagulation, and fibrinolysis in sickle cell disease: Their possible role in vascular occlusion. Blood Coagul Fibrinolysis 1991;2:341-353.
14. Mohan JS, Lip GYH, Wright J, Bareford D, Blann AD. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: Relationship to genotype and to inflammation. Blood Coagul Fibrinolysis 2005;16:209-214.
15. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: A curious paradox. Am J Med 2003;115:721-728.
16. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99:36-43.
17. Pattanapanyasat K, Gonwong S, Chaichompoo P, Noulsri E, Lerdwana S, Sukapirom K, Siritanaratkul N, Fucharoen S. Activated platelet-derived microparticles in thalassaemia. Br J Haematol 2007;136:462-471.
18. van Beers EJ, Schaap MCL, Berkmans RJ, Nieuwland R, Sturk A, van Doormaal FF, Meijers JC, Biemond BJ, CURAMA study group. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009;94:1513-1519.
19. Piccin A, Murphy WG, Smith OP. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 2007;21:157-171.
20. Horstman LL, Ahn YS. Platelet microparticles: A wide-angle perspective. Crit Rev Oncol Hematol. 1999;30(2):111-142.
21. Owens III AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011;108:1284-1297.
22. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006;48:180-186.
23. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59:277-287.
24. Freyssinet JM. Cellular microparticles: What are they bad or good for? J Thromb Haemost 2003;1:1655-1662.
25. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cellderived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009;101:439-451.
26. Nieuwland R, Sturk A. Why do cells release vesicles? Thromb Res 2010;125(Suppl. I):S49-S51.
27. Holme PA, Solum NO, Brosstad F, Roger M, Abdelnoor M. Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and Western blotting. Thromb Haemost 1994;72:666-671.
28. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996;93:229-237.
29. Habib A, Kunzelmann C, Shamseddeen W. Elevated levels of circulating procoagulant microparticles in patients with -thalassemia intermedia. Haematologica. 2008;93(6):941-942.
30. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009;94(11):1481-1484.
31. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683.
32. Chen Y, Davis-Gorman G, Watson RR, McDonagh PF. Platelet CD62p expression and microparticle in murine acquired immune deficiency syndrome and chronic ethanol consumption. Alcohol Alcohol 2003;38:25-30.
33. Shigeta O, Kojima H, Jikuya T, Terada Y, Atsumi N, Sakakibara Y, Nagasawa T, Mitsui T. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569-574.
34. Horigome H, Hiramatsu Y, Shigeta O, Nagasawa T, Matsui A. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol 2002;39:1072-1077.
35. Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002;51:2840-2845.
36. Geiser T, Buck F, Meyer BJ, Bassetti C, Haeberli A, Gugger M. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002;69(3): 229-234.
37. Wethers DL. Sickle cell disease in childhood: Part I. Laboratory diagnosis, pathophysiology and health maintenance. Am Fam Physician 2000;62:1013-1020.
38. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16.
39. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: Mechanisms, diagnosis, and management. Hematol Oncol Clin North Am 2005;19:881-896.
40. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998;92:3082-3089.
41. Strouse JJ, Hulbert ML, DeBaun MR, Jordan LC, Casella JF. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 2006;118:1916-1924.
42. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol 2002;9:123-126.
43. Pattanapanyasat K, Noulsri E, Fucharoen S, Lerdwana S, Lamchiagdhase P, Siritanaratkul N, Webster HK. Flow cytometric quantitation of red blood cell vesicles in thalassemia. Cytometry B Clin Cytom 2004;57:23-31.
44. Rautou PE, Vion AC, Amabile N, Chironi G, Simon A, Tedgui A, Boulanger CM. Microparticles, vascular function, and atherothrombosis. Circ Res 2011;109:593-606.
45. Smiley D, Dagogo-Jack S, Umpierrez G. Therapy insight: Metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab 2008;4:102-109.
46. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000;101:841-843.
47. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001;85:639-646.
48. Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011;105:396-408.
49. Schroit AJ, Madsen JW, Tanaka Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J Biol Chem 1985;260:5131-5138.
50. Allan D, Limbrick AR, Thomas P, Westerman MP. Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature 1982;295:612-613.
51. Adams GT, Snieder H, McKie VC, Clair B, Brambilla D, Adams RJ, Kutlar F, Kutlar A. Genetic risk factors for cerebrovascular disease in children with sickle cell disease: Design of a case-control association study and genomewide screen. BMC Med Genet 2003;4:6.
52. Westerman MP, Cole ER, Wu K. The effect of spicules obtained from sickle red cells on clotting activity. Br J Haematol 1984;56:557-562.
53. Michaeli JM, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Haematol 1992;87:71-74.
54. Ardoin SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol 2007;66:159-165.
55. Vallar L, Regnault V, Latger-Cannard V, Lecompte T. Beta 2-glycoprotein I binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost 2001;85:314-219.
56. Horvath B, Hegedus D, Szapary L, Marton Z, Alexy T, Koltai K, Czopf L, Wittmann I, Juricskay I, Toth K, et al. Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol 2004;9:31-34.
57. Machado RF. Pulmonary hypertension in sickle cell disease. PVRI Review 2009;1:6-12.
58. Onyekwere OC, Campbell A, Teshome M, Onyeagoro S, Sylvan C, Akintilo A, Hutchinson S, Ensing G, Gaskin P, Kato G, et al. Pulmonary hypertension in children and adolescents with sickle cell disease. Pediatr Cardiol 2008;29:309-312.
59. Kato GJ, Hsieh M, Machado R, Taylor 6th J, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT. Cerebrovascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006;81:503-510.
60. Tomer A, Harker LA, Kasey S, Eckman Jr. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001;137:398-407.
61. Rees DC, Williams TN, Gladwin MT. Sickle cell disease. Lancet 2010;376:2018-2031.
62. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin North Am 2005;19:771-784.
63. Roseff SD. Sickle cell disease: A review. Immunohematology 2009;25:67-74.
64. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Polonifi A, Moyssakis I, Diamanti-Kandaraki E, Papalambros E. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Ann Hematol 2005;84:353-357.
65. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861-2868.
66. Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O,Woodhams B, Maier-Redelsperger M, et al. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 2012;107:1044-1052.
67. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle cell disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007;110:2166-2172.
68. Tsironi M, Aessopos A. The heart in sickle cell disease. Acta Cardiol 2005;60:589-598.
69. Cheung YF, Chan GC, Ha SY. Arterial stiffness and endothelial function in patients with beta-thalassemia major. Circulation 2002;106:2561-2566.
70. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: Current understanding and future directions. J Am Coll Cardiol 2011;47:1511-1522.
71. Aessopos A, Farmakis D, Tsironi M, Diamanti-Kandarakis E, Matzourani M, Fragodimiri C, Hatziliami A, Karagiorga M. Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis 2007;191:427-332.
72. Lemogoum D, Van Bortel L, Najem B, Dzudie A, Teutcha C, Madu E, Leeman M, Degaute JP, van de Borne P. Arterial stiffness and wave reflections in patients with sickle cell disease. Hypertension 2004;44:924-929.
73. Bellien J, Favre J, Iacob M, Gao J, Thuillez C, Richard V, Joannides R. Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans. Hypertension 2010;55:674-680.
74. Elsharawy MA, Moghazy KM, Shawarby MA. Atherosclerosis in sickle cell disease - A review. Int J Angiol 2009;18:62-66.
75. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris Jr SM, Gladwin MT. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005;294:81-90.
76. Fuentes QE, Fuentes QF, Andre's V, Pello OM, de Mora JF, Palomo GI. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2012, [Epub ahead of print]